potassium 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetate | 83881-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: potassium 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetate
• 英文别名: Potassium (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetate；potassium;2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetate
• CAS: 83881-50-9
• 化学式: C₂₁H₂₄ClN₂O₃*K
• 分子量: 426.984
• InChiKey: HLVJBBWMBPQZAE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.18
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  西替立嗪甲基酯 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 以56%的产率得到potassium 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetate
  参考文献：
  名称：

  2-[4-(Diphenylmethyl)-1-piperazinyl]-acetic acids and their amides

  摘要：

  新的2-[4-(二苯甲基)-1-哌嗪基]-乙酸，它们的酰胺和盐，其制备方法以及治疗组合物。这些化合物的化学式为##STR1##其中Y= -OH或-NH2；X和X'=H，卤素，烷氧基或三氟甲基；m=1或2，n=1或2。2-[4-(二苯甲基)-1-哌嗪基]-乙酸的酰胺可以通过将1-(二苯甲基)-哌嗪基与ω-卤代乙酰胺反应来制备，或者通过将ω-[4-(二苯甲基)-1-哌嗪基]-烷醇的碱金属盐与2-卤代乙酰胺反应来制备，或者通过将氨与2-[4-(二苯甲基)-1-哌嗪基]-乙酸的卤化物或烷基酯反应来制备，而2-[4-(二苯甲基)-1-哌嗪基]-乙酸是通过水解相应的酰胺或较低烷基酯来制备的。这些化合物特别具有抗过敏、解痉和抗组胺活性。

  公开号：

  US04525358A1

文献信息

• Process for obtaining cetirizine dihydrochloride
  申请人：Lussana Massimiliano

  公开号：US20090030205A1

  公开（公告）日：2009-01-29

  Process for the synthesis of cetirizine dihydrochloride, wherein (a) a solution of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol in 1-7 volumes, referred to the weight of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol, of an organic solvent having a boiling point higher than 90° C. and being chosen from the group consisting of aliphatic, cycloalifatic or aromatic solvents is provided, whereafter (b) per equivalent of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, 1-2 equivalents of a metal haloacetate or of haloacetic acid, as well as 3-7 equivalents of an alkaly metal hydroxyde are added to the solution as per (a), providing a reaction mixture, where 0.05-0.3 volumes, referred to the weight of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, of water and 0.1-1.2 volumes, referred to the weight of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, of a polar aprotic, water miscible solvent are added, keeping the internal temperature of the reaction mixture below 60° C., whereafter (c) the cetirizine base formed within the reaction mixture is converted into its dihydrochloride salt and isolated as such.

  盐酸西替利嗪的合成过程，其中 (a) 在一种有沸点高于90°C的有机溶剂中提供2-[4-(α-苯基-p-氯苄基)哌嗪-1-基]}乙醇的1-7倍体积的溶液，所述有机溶剂选自脂肪族、环脂族或芳香族溶剂组成的群体，然后 (b) 每当使用2-[4-(α-苯基-p-氯苄基)哌嗪-1-基]}乙醇的当量时，向所述溶液中添加1-2当量的金属卤代乙酸盐或卤代乙酸，以及3-7当量的碱金属氢氧化物，形成反应混合物，其中向所述(a)中的溶液中添加0.05-0.3倍体积的水和0.1-1.2倍体积的极性无水剂，保持反应混合物的内部温度低于60°C，然后 (c) 在反应混合物中形成的西替利嗪碱转化为其盐酸二水合物盐并作为此类盐分离。
• Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
  申请人：Robinson B. Cynthia

  公开号：US20050026890A1

  公开（公告）日：2005-02-03

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an antihistamine for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

  一种制药或兽医组合物，包括第一活性剂，所述第一活性剂选自去氢表雄酮和/或去氢表雄酮硫酸盐，或其盐，并且第二活性剂包括一种抗组胺药物，用于治疗哮喘、慢性阻塞性肺疾病或任何其他呼吸系统疾病。该组合物以各种制剂和套装形式提供。本专利的产品应用于哮喘、慢性阻塞性肺疾病或任何其他呼吸系统疾病的预防和治疗。
• Process for obtaining Cetirizine dihydrochloride
  申请人：Cosma S.p.A.

  公开号：EP2019096A1

  公开（公告）日：2009-01-28

  Process for the synthesis of cetirizine dihydrochloride, wherein (a) a solution of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol in 1-7 volumes, referred to the weight of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol, of an organic solvent having a boiling point higher than 90°C and being chosen from the group consisting of aliphatic, cycloalifatic or aromatic solvents is provided, whereafter (b) per equivalent of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, 1-2 equivalents of a metal haloacetate or of haloacetic acid, as well as 3-7 equivalents of an alkaly metal hydroxyde are added to the solution as per (a), providing a reaction mixture, where 0,05-0,3 volumes, referred to the weight of 2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, of water and 0,1-1,2 volumes, referred to the weight of 2-(4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol employed, of a polar aprotic, water miscible solvent are added, keeping the internal temperature of the reaction mixture below 60°C, whereafter (c) the cetirizine base formed within the reaction mixture is converted into its dihydrochloride salt and isolated as such.

  合成盐酸西替利嗪的过程，其中(a)提供一种有机溶剂的溶液，所述有机溶剂的沸点高于90°C，并选自脂肪族、环脂族或芳香族溶剂，所述溶液中的重量为2-[4-(α-苯基-p-氯苯甲基)哌嗪-1-基]}乙醇的1-7倍，随后(b)每当使用等量的2-[4-(α-苯基-p-氯苯甲基)哌嗪-1-基]}乙醇，就向上述(a)中的溶液中加入1-2当量的金属卤代酸盐或卤代乙酸以及3-7当量的碱金属氢氧化物，从而提供反应混合物，其中加入0.05-0.3倍体积的水，参照所使用的2-[4-(α-苯基-p-氯苯甲基)哌嗪-1-基]}乙醇的重量，以及0.1-1.2倍体积的极性无水溶剂，参照所使用的2-[4-(α-苯基-p-氯苯甲基)哌嗪-1-基]}乙醇的重量，保持反应混合物的内部温度低于60°C，随后(c)将在反应混合物中形成的西替利嗪碱转化为其盐酸二水合物盐并分离出来。
• Pulmonary delivery for bioconjugation
  申请人：CONJUCHEM, INC.

  公开号：US20040156859A1

  公开（公告）日：2004-08-12

  Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.

  本发明公开了一种可与感兴趣的部位形成共价键或已与肺溶液蛋白形成共价键的治疗剂的肺部输送方法和组成物。本发明中有用的治疗剂包括伤口愈合剂、抗生素、抗炎剂、抗氧化剂、抗增殖剂、免疫抑制剂、抗感染和抗癌剂。
• NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF
  申请人：Zelikovitch Lior

  公开号：US20110230496A1

  公开（公告）日：2011-09-22

  A process for preparing pure levocetirizine and salts thereof, e.g., the levocetirizine dihydrochloride, and a pharmaceutical composition comprising levocetirizine dihydrochloride produced by the process are disclosed.

  本发明公开了一种制备纯左西替利嗪及其盐，例如左西替利嗪二盐酸盐的方法，以及由该方法生产的含左西替利嗪二盐酸盐的药物组合物。